Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guideGynecologic Oncology.  155:161-169. 2019
2019 Gynecologic oncology providers endorse practice-changing impact of communication skills trainingGynecologic Oncology.  153:633-638. 2019
2019 Utilization of an alternative docetaxel-based intraperitoneal chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinomaAmerican Journal of Clinical Oncology.  42:12-16. 2019
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinomaCell Growth and Differentiation.  16:813-824. 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancerJournal of Nutrition.  148:1253-1260. 2018
2018 Lay patient navigators’ perspectives of barriers, facilitators and training needs in initiating advance care planning conversations with older patients with cancerJournal of Palliative Care.  33:70-78. 2018
2018 Vulvar cancer as a result of GATA2 deficiency, a rare genetic immunodeficiency syndromeObstetrics and Gynecology.  132:1112-1115. 2018
2017 Values and worries of ovarian cancer patientsGynecologic Oncology.  147:433-438. 2017
2017 Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning ConversationsJournal of Pain and Symptom Management.  53:682-692. 2017
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:70. 2016
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:1-11. 2016
2016 Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan InterventionCancer.  122:3232-3242. 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinomaGynecologic Oncology.  142:25-29. 2016
2016 Endometrial Cancer: Using Evidence to Impact Practice and PolicyJournal for Nurse Practitioners.  12:395-402. 2016
2015 Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patientsGynecologic Oncology.  139:413-418. 2015
2014 A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapyGynecologic Oncology.  132:531-536. 2014
2014 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.Journal of Reproductive Medicine.  59:113-120. 2014
2013 Vulvar histoplasmosis as a rare cause of genital ulcerationObstetrics and Gynecology.  122:449-452. 2013
2013 The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapyObstetrical and Gynecological Survey.  68:291-292. 2013
2013 The effect of the apprise mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapyInternational Journal of Gynecological Cancer.  23:367-371. 2013
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant womenJournal of Reproductive Medicine.  58:279-284. 2013
2013 Incidence of port site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patientsGynecologic Oncology.  131:123-126. 2013
2012 Smoothened antagonists reverse taxane resistance in ovarian cancerMolecular Cancer Therapeutics.  11:1587-1597. 2012
2012 Treatment of chemotherapy-induced anemia in ovarian cancer patients: Does the use of erythropoiesis-stimulating agents worsen survival?International Journal of Gynecological Cancer.  22:786-791. 2012
2012 Stem cell pathways contribute to clinical chemoresistance in ovarian cancerClinical Cancer Research.  18:869-881. 2012
2011 Cervical conization and the risk of preterm deliveryAmerican Journal of Obstetrics and Gynecology.  205:19-27. 2011
2011 The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancerClinical Ovarian Cancer.  4:34-37. 2011
2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer modelGynecologic Oncology.  121:193-199. 2011
2010 Overcoming TRAIL resistance in ovarian carcinomaGynecologic Oncology.  119:157-163. 2010
2010 The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancerClinical Ovarian Cancer.  3:52-55. 2010

Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2023
  • Private Grant  awarded by GENMAB 2018 - 2023
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago 2018 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Private Grant  awarded by Genentech 2017 - 2022
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2022
  • Private Grant  awarded by MATEON THERAPEUTICS, INC. 2016 - 2021
  • Private Grant  awarded by PLEXXIKON 2016 - 2021
  • Private Grant  awarded by ABBVIE INC 2015 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by LICOR, INC. 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2018
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Gynecologic Oncology Group Clinical Trials  awarded by GYNECOLOGIC ONCOLOGY GROUP 2012 - 2016
  • OB/GYN Faculty Research Career Development Program  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2010 - 2015
  • Private Grant  awarded by ASTRAZENECA AB 2014 - 2015
  • Death Receptor-Mediated Apoptosis and Therapy Strategies in Ovarian Cancer  awarded by National Cancer Institute/NIH/DHHS 2007 - 2013
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2005
  • UAB Hospital, Internship 2006
  • UAB Hospital, Residency 2009
  • UAB Hospital, Postdoctoral Fellowship 2012
  • Full Name

  • Kerri Bevis